The specific purpose of this study was the assessment of A5935G, G5949A, G6081A, G6267A mutations in MT-CO1 and T9540C in MT-CO3, and alterations detected during the analysis of MT-CO gene fragments in subject and control groups. A secondary aim was to assess the relationship between MT-CO1 and MT-CO3 gene alterations and endometrial cancer incidence and evaluation of the prognostic value of MT-CO1 and MT-CO3 gene alterations.
INTRODUCTION
In recent years, there has been a rise in the number of reported mtDNA mutations predisposing to neoplasm growth. There are few studies concerning MT-CO genes mutations on endometrial cancer development. Thus, the present study is an attempt to complete the knowledge concerning the meaning of mtDNA disorders in endometrial cancer development.
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We would like to focus on A5935G, G5949A, G6081A, G6267A mutations in MT-CO1 and T9540C in MT-CO3 presence and other variants of MT-CO1 and MT-CO3 gene fragments in the study population. The mutations selected for this research occur in prostate, breast, pancreatic cancer, colorectal cancer as well as ulcerative colitis [1, 2] .
Alterations of MT-CO can lead to dysfunction of mitochondrial respiratory chain complex IV, which leads to changes in cellular metabolism, resulting in modifications to the cell's susceptibility to cancerous transformation [3] [4] [5] .
A5935G, G5949A, G6081A, G6267A are nonsynonymous mutations which stem from transition (A-G or G-A) and change the amino acid in protein product of MT-CO1.
The A5935G mutation exchanges asparagine for serine at position 11 in cytochrome c oxidase's first subunit, resulting in protein function impairment. Substitution of an asparagine radical for a serine radical prevents the formation of multiple hydric bonds, which may disrupt protein tertiary structure. In addition, the alteration can destabilize transmembrane protein (conduit D) structure, which serves as a pathway for proton transfer in oxygen reduction [1, 6, 7] .
Another G5949A mutation, detected in prostate cancer, triggers premature formation of STOP codon in MT-CO1, which results in a shorter polypeptide length of 15 amino acids, instead of 513 amino acids. The shorter polypeptide product is highly unstable and quickly breaks down. In effect, this mutation decreases COX1 and COX2 levels. The unstable protein structure and its decreased concentration impairs the assembly process of oxidative phosphorylation IV subunit [1, 7, 8] .
The G6081A mutation introduces alanine radical instead of threonine into the 60 th position on cytochrome c oxidase. In most Eukaryotes, 60 th position of polypeptide contains amino acids with a small molecular weight such as alanine or glycine. A replacement of alanine with threonine with its branched lateral chain in the 60 th position and close proximity to heme group iron stabilizer histidine can disrupt protein helix structure. Polypeptide secondary structure dysfunction can affect electron transfer via α heme [7, 9, 10] .
The 6267G>A change prompts the replacement of alanine radical with threonine at 122 th locus of the polypeptide. Similarly to A5935G and G6081A mutations, alanine radical in this locus is highly evolutionarily preserved. According to the authors, cells with G6267A mutation have restricted growth on culture medium without glucose. It can suggest respiratory chain failure due to this mutation [2, 7] .
The T9540C mutation is a T=>C transition, characteristic of oxidative stress damage [11] . This mutation causes a change in mRNA codon from UUA to CUA, which does not, however, lead to a change of amino acids in the protein chain. It is therefore a silent mutation [12] . 
MATERIAL AND METHODS

Ethical aspect
The study was approved by the local ethic committee of "Polish Mother's Memorial Hospital" Research Institute (ethical agreement 3/2011).
DNA isolation
Genomic and mitochondrial DNA were extracted from formalin-fixed, paraffin-embedded (FFPE) endometrial cancer and benign endometrial hyperplasia samples by using the QIAamp DNA FFPE Tissue Kit (Qiagen, Germany) in accordance with the manufacturer's protocol (purified DNA is free of proteins, nucleases, and other impurities).
The concentration (A260) and purity (A260/A280 ratio) of isolated DNA were determined by using a PicoDrop -spectrophotometer (Picodrop Limited, United Kingdom). The extracted pure DNA was used in amplification reactions or stored at −20°C.
Polymerase chain reaction amplification
The purified DNA was used as a template for PCR amplification. The reaction mixture in 20 μL volume contained 50 ng of DNA, 1UTaq DNA polymerase (Promega, USA), 1.5 mM MgCl 2 , 0.25 mM each of dATP, dCTP, dGTP, and dTTP, and 0.5µM of the primers.
Amplification was performed with a thermal cycler, Gene-Amp PCR System 9700 (Applied Biosystems, USA).
The following COX1 and COX3 -specific sets of primers were used: COX1 For: 5´-GAAAATCACCTCGGAGCTGG-3Ŕ ev: 5´-GATGGTTAGGTCTACGGAGG-3
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For: 5´-GGCCTTCGATACGGGATAAT-3Ŕ ev: 5´-ATGGTGAGCTCAGGTGATTG-3T hermal cycling conditions for PCR reactions included an initial denaturation step at 95°C for 5 minutes followed by 30 cycles of a denaturation step at 95°C for 30 seconds, a primer annealing step at 60°C for 30 seconds, an extension step at 72°C for 30 seconds, and a final step at 72°C for 7 minutes.
Microchip electrophoresis of DNA fragments
The PCR amplification products were separated and analyzed on the automated microchip electrophoresis system MCE-202 MultiNa (Shimadzu, Japan) using the DNA--1000 kit according to the manufacturer's protocol. A SYBR Gold fluorescent dye for DNA staining (Invitrogen, USA) and PhiX174 DNA/Hae III Markers (Promega, USA) were used to determine the size of the PCR products.
Sequencing
Amplification products were purified using MiniElute PCR Purification Kit (Qiagen, Germany). The sequencing reactions were run using a Big Dye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, USA) on the GeneAmp PCR System 9700 using standard sequencing protocols. Sequence analysis was performed by using the same primers as previously used in preamplification step.
The PCR products were purified to eliminate unincorporated primers and dNTPs using BigDye XTerminator Purification Kit and then subjected to separation by the 3130xl GeneGenetic Analyzer (Applied Biosystems).
The DNA sequences were analyzed using DNA Baser Sequence Assembler. 
Statistical analysis
RESULTS
The T9540C mutation in MT-CO3 was detected in one patient from the subject group.
None of the remaining mutations (A5935G, G5949A, G6081A, G6267A into MT-CO1) were detected in either patient group.
Analysis of MT-CO1 and MT-CO3 gene fragments revealed 8 alterations (5 and 3 respectively). The alterations detected in 9% of the study group and 8% of the control group. The most common alterations included: A6047G with an incidence of 2/100 (2%) in the study group and 1/25 (4%) in the control group and T5999C with an incidence www. journals.viamedica.pl/ginekologia_polska of 2/100 (2%) in the study group and 1/25 (4%). T6152C, G9477A mutations were also detected in the study group, each with an incidence of 2/100 (2%).
The remaining variants G5913A, G9575A, A9545G occurred in 1% (1/100) of the study group while A6052G was found in 4% (1/25) of the control group.
As the above data demonstrates, only 2 MT-CO gene variants were detected in both the study and control group. Given their low incidence testing for these mutations seems to be unwarranted.
In the study group MT-CO1 and MT-CO3 gene variants were detected, whereas in the control group only alterations in MT-CO1 were observed. Table 1 shows a summary of MT-CO1 and MT-CO3 genes mutations including medical history data from patients in the study and control groups.
Due to the rarity of the aforesaid alterations statistical analysis could not be performed as it would be unreliable.
Among the detected mutations are those observed in prostate cancer, pancreatic cancer, glioblastoma multiforme, hydatidiform mole, ovarian and thyroid cancers, head and neck cancers ( Table 2 ). The remaining 3 alterations were described for the first time in this study ( Table 3) .
Three of the detected variants are transitions (A-G or G-A) leading to amino acid change in the protein product of MT-CO1 and MT-CO3. The effect of the amino acid change on polypeptide structure and function was analyzed based on UniProt database [19] .
The G5913A mutation substitutes asparagine radical for aspartate into the 4 th locus of COX1 subunit. Amino acids presented in the 4 th locus are different for Eukaryote species. As the data in the chart implies, the sequence containing the mutation is not evolutionarily preserved. Therefore it seems safe to assume that the amino acid change does not affect polypeptide properties.
The A6052G mutation, which causes substitution of asparagine with serine in the 50 th locus of cytochrome c oxidase's first subunit, is highly evolutionarily modified. Poor evolutionary variability of a given sequence may suggest that amino acid substitution does not alter protein structure or function.
Also the G9477A mutation causing the substitution of valine with isoleucine at locus 91 does not change the phenotype. One of the human variants of polypeptide first subunit of cytochrome c oxidase is the occurence of isoleucine at locus 91. Isoleucine located at locus 91 occurs in 17.5% of the European and 6.7% of the African population [19] . The remaining MT-CO1 and MT-CO3 gene variants detected in this study do not cause any amino acid change. 6047  6152  5999  5913  9477 A -adenine, C -cytosine, G -guanine, T -thymine, Leu -leucine, Val -valine, Ala -alanine, Asp -asparagine, Asn -aspartate, Ile -isoleucine 
Nucleotide position number
DISCUSSION
In recent years, there has been a rise in the number of reported congenital and somatic mutations as well as mtDNA polymorphisms predisposing to neoplasm growth. Among the mutations tested in the subject population the T9540C mutation in MT-CO3 was detected in one of the patients diagnosed with endometrial cancer. Due to the mutation's sporadic occurrence, 1/100 patients, the case is statistically irrelevant and does not qualify for further statistical analysis.
The T9540C reported in breast cancer is a germline mutation, i.e. one present in both cancerous and healthy cells of the same individual. Germline mutations are transmitted from one generation to the next [20] . Likewise, in case of ovarian cancer, investigators determined the T9540C variant to be a germline mutation based on tumor and healthy cell samples taken from sons of mothers diagnosed with ovarian cancer [21] . The T9540C mutation also occurs in ulcerative colitis, chronic inflammatory disease predisposing to colorectal cancer [22] .
Analysis of MT-CO1 and MT-CO3 gene fragments for other changes revealed: variants in MT-CO1 (A6047G, T6152C, T5999C, G5913A, A6052G) and in MT-CO3 (G9477A, A9545G, G9575A).
Among the detected mutations are those observed in other neoplasms: prostate cancer and hydatidiform mole (G5913A) [1, 16] , pancreatic tumor and glioblastoma multiforme (A6047G, T5999C) [13, 14] , ovarian and thyroid cancers (G9477A) [17, 18] , head and neck squamous cell carcinoma (T6152C) [15] . The remaining 3 alterations (A6052G, A9545G, G9575A) were described in this study for the first time.
The G5913A mutation desribed by Petros at al. [1] is a transition (G>A) which causes substitution of aspartate with asparagine at 4 th locus of COX1 product. The locus where amino acid substitution occurred is highly evolutionarily modified. It is therefore improbable that the changed amino acid affects the polypeptide's phenotype [1, 7] . The same mutation occurs in hydatidiform mole, a disease which predisposes to choriocarcinoma [16] .
Researchers have suggested a relationship between A6047G and T5999C mutations occuring in glioblastoma multiforme and oxidative stress in cancerous cells. They suspect there is a correlation between the transition and both respiratory chain failure and an increased concentration of reactive oxygen species [13, [23] [24] [25] [26] . Investigators of mtDNA variants in pancreatic cancer have inferred a similar conclusion [14] .
In the course of study on somatic mutations in human thyroid cancer, where 68 patients were enrolled, MT-CO1 and MT-CO3 gene mutations were detected in 9 patients. The G9477A mutation occured in tumoral and adjacent healthy tissue samples from 3 patients. Scientists demonstrated a prevalence of variants of genes encoding complex IV in malignant tumors compared with benign neoplasms [17] . The G9477A mutation, also described in ovarian cancer, increases the risk of its incidence by 1.27 times [18] . Another T6152C mutation was first described in head and neck squamous cell carcinomas. Researchers focused mainly on the analysis of D-loop vatiants, but did not imply any statistically significant relationship between detected alterations and head and neck cancers as the tested variants were too rare [15] .
The variants of MT-CO1 and MT-CO3 described in this study for the first time are also transitions. One of them, namely A6052G, introduces serine instead of asparagine into the 50 th locus of COX1 subunit. The sequence where the amino acid change occurred is not evolutionarily preserved. Given the low evolutionary diversity of the studied sequence it seems safe to assume that amino acid substitution does not affect polypeptide structure or function [19] . The two remaining variants detected in this study do not trigger any amino acid change in the protein product.
Due to the limited reports on MT-CO1 and MT-CO3 gene mutations in endometrial cancer, selected mutations and variants detected in endometrial cancer patients and the study group during MT-CO gene fragments testing were subject to further analysis.
It was a rather difficult task since compared with the variants in hypervariable D-loop region these mutations occur only in a small portion of the studied neoplasms. Petros et al. [1] studied mutations in MT-CO1 occuring in only 11-12% of the population with prostate cancer and in < 2% of the control group. Among the 17 patients diagnosed with glioblastoma multiforme only one carried an MT-CO1 gene mutation, the remaining alterations were mostly located in D-loop [13] . Similarly, out of 68 thyroid cancer patients MT-CO1 and MT-CO3 gene mutations were detected in 9 cases [17] . Nevertheless, the influence of mtDNA mutations encoding respiratory chain subunits impairs energy and metabolic processes in cells, and affects the function of tissues and thus the whole body. The importance of this question prompted us to study MT-CO1 and MT-CO3 gene mutations in endometrial cancer.
CONCLUSIONS
The analysis performed indicates none of the remaining MT-CO1 mutations (A5935G, G5949A, G6081A, G6267A) occur in endometrial cancer.
Three new alterations detected in this study (A6052G, A9545G, G9575A) were described for the first time.
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